Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2026—The 2024 revision of the 2017 McDonald criteria for diagnosing multiple sclerosis allows the kappa-free light chain index to replace oligoclonal band detection in cerebrospinal fluid analysis.
February 2026—Washington University in St. Louis implemented a clinical decision support intervention to reduce unnecessary magnesium testing.
January 2026—When new biomarkers become part of clinical practice, the fundamental question—Will this work?—soon gives way to an equally important group of interrogatives: who, what, when, where, why, and how. At Michigan Medicine, introducing two biomarkers—glial fibrillary acidic protein, or GFAP, and ubiquitin C-terminal hydrolase L1, or UCH-L1—into the emergency department to evaluate traumatic brain injury emphasized the how of the matter.
January 2026—Translating cytokine science into better cancer care was the focus of a presentation at last year’s ADLM meeting, where the toxicities associated with CAR T-cell therapy were explained with cases and the need to measure cytokines was made clear.
January 2025—In the 2025 edition of the CAP accreditation checklists are new requirements on humidity, specimen self-collection, body fluid crystal analysis, and pneumatic tube transport of blood specimens for platelet aggregation or other platelet function testing. The new checklist edition was released last year on Dec. 9.
December 2025—Northwestern Medicine Delnor Hospital piloted a program using drones for transporting patient samples and blood products between the hospital and cancer center. The program, using Valqari drones, achieved a 100% success rate in delivering 303 packages without any damage or temperature fluctuations.
December 2025—Massachusetts General Hospital implemented a clinical decision support solution to reduce unnecessary CBC and differential orders, particularly for inpatients. The solution involved an interruptive alert that targeted daily, more than daily, and as-needed orders, recommending alternative orders like CBCs without differentials.
November 2025—The Color Atlas of Body Fluids: An Illustrated Field Guide Based on Proficiency Testing, second edition, features over 1,200 photographs, 70 photo galleries, 360 illustrations, and 15 videos. The atlas, which completes the CAP’s Color Atlas series, uses images from CAP’s laboratory proficiency testing, providing authenticity and real-world variability.
October 2025—For all the effort, redos, build-outs, planning, talking, and time that went into revamping blood product orders at Children’s Healthcare of Atlanta, the essence can be …
October 2025—Complementary and integrative medicine (CIM) has become gradually more popular and is accepted by a small but significant group of patients in tandem with traditional medicine. CIM providers often advocate a mix of conventional tests with special test panels that may include tens to hundreds of tests that conventional providers wouldn’t order. For those who lead laboratory stewardship efforts, it can be a challenge.
